Global antibody conjugate drug trade is in full swing, China to meet the anti-cancer "magic bullet" research and development boom.

Sep 03,2024

Global antibody conjugate drug trade is in full swing, China to meet the anti-cancer "magic bullet" research and development boom.

51% of clinical ADC drugs in China enter phase II and beyond trials

View Details

03

2024/09

Innovative anti-cytomegalovirus drugs put into clinical use in China to fill the gap in the treatment of refractory CMV after transplantation

Innovative anti-cytomegalovirus drugs put into clinical use in China to fill the gap in the treatment of refractory CMV after transplantation

Adult transplant recipients with CMV infection or disease bring new treatment options

03

2024/09

Can the acceleration of global tumor vaccine research and development be the gospel of conquering cancer?

Can the acceleration of global tumor vaccine research and development be the gospel of conquering cancer?

Global research and development of cancer vaccines to prevent and treat cancer

03

2024/09

Pien Tze Huang Pharmaceutical Another Innovative Tumor Drug Approved for Clinical

Pien Tze Huang Pharmaceutical Another Innovative Tumor Drug Approved for Clinical

DLBCL is the most common non-Hodgkin lymphoma

03

2024/09

The enhanced version of oncolytic virus is launched to "dissolve" cancer cells is its unique trick.

The enhanced version of oncolytic virus is launched to "dissolve" cancer cells is its unique trick.

Oncolytic viruses can "lyse" tumor cells"

03

2024/09

Legendary biological new products approved, drug Mingjunuo products new indications approved: "sky-high price" CAR-T therapy when can really go to the public?

Legendary biological new products approved, drug Mingjunuo products new indications approved: "sky-high price" CAR-T therapy when can really go to the public?

Legendary Bio announced that the company's self-developed cell therapy product, Kawei Di.®

03

2024/09

Medical and Health Industry Weekly | "Ruezheng Gene" focuses on the development of gene editing drugs in non-viral vectors; Xianbo Biology completes round A financing of 0.2 billion yuan

Medical and Health Industry Weekly | "Ruezheng Gene" focuses on the development of gene editing drugs in non-viral vectors; Xianbo Biology completes round A financing of 0.2 billion yuan

Medical and health industry innovation continues to emerge

03

2024/09

Let bacteria "eat" tumors to reduce birth defects by 1%

Let bacteria "eat" tumors to reduce birth defects by 1%

Global biopharmaceutical market is booming

03

2024/09

2024 Anti-tumor Drug Innovation Research and Development Conference and "2023 China Anti-tumor New Drug Clinical Research Review" Conference Successfully Held

2024 Anti-tumor Drug Innovation Research and Development Conference and "2023 China Anti-tumor New Drug Clinical Research Review" Conference Successfully Held

2024 Antineoplastic Drug Innovation R & D Conference

03

2024/09

The Summit Forum on Oncolytic Virus Innovative Drug Research Successfully Concluded, Clinical Research and Results Transformation Future

The Summit Forum on Oncolytic Virus Innovative Drug Research Successfully Concluded, Clinical Research and Results Transformation Future

Study on Innovative Drug of Oncolytic Virus

Veronide
Picture Name

Focus on us

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Contact Information

020-32030745

Monday to Friday 9:00~17:00

Virotech@virot.cn

Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City

Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.

粤ICP备XXXXXXXX号

Tags | city substation  | Business License | Powered by www.300.cn